botaretigene sparoparvovec

AXP000260.1 · Viral vector gene therapy

Platform
AAV5 vector
Targets
RPGR
Originator
MeiraGTx
Sponsor
Johnson & Johnson

Names

NameTypeSource
botaretigene sparoparvovecpreferred namecurator
bota-vecsynonymcurator
AAV-RPGRformer codecurator
MGT009former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 5
Strain
AAV5
Replication
non replicating
Transgenes
RPGR
Route
subretinal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06646289A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)Active not recruitingPhase 22024-10-102030-10-2424X-Linked Retinitis Pigmentosa
NCT04794101Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneActive not recruitingPhase 32020-12-042029-09-2097X-Linked Retinitis Pigmentosa
NCT04671433Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneCompletedPhase 32020-12-042024-09-30105X-Linked Retinitis Pigmentosa

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42847595Microperimetry Sensitivity Changes at the Functional Transition Zone and at the EZ Margins in X-Linked Retinitis Pigmentosa Treated With Gene Therapy.Translational vision science & technology2026name in abstract: AAV-RPGR

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42576225Efficacy and safety of AAV RPGR gene therapy in X-linked retinitis pigmentosa: a systematic review and meta-analysis.Journal of translational medicine2026name in title: AAV-RPGR
PMID 42652548Functional Outcomes and Ocular Safety of Subretinal AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: A Systematic Review and Meta-Analysis.Journal of clinical medicine2026name in title: AAV-RPGR
PMID 38339118AAV-RPGR Gene Therapy Rescues Opsin Mislocalisation in a Human Retinal Organoid Model of RPGR-Associated X-Linked Retinitis Pigmentosa.International journal of molecular sciences2024name in title: AAV-RPGR
PMID 31612744RPGR gene therapy presents challenges in cloning the coding sequence.Expert opinion on biological therapy2020name in abstract: AAV-RPGR

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIAEY000443Ocular Gene TherapyNATIONAL EYE INSTITUTEWU, ZHIJIAN2017–2017name in abstract: AAV-RPGR

Notes

AAV5 vector delivering RPGR to rod and cone photoreceptors for X-linked retinitis pigmentosa, given subretinally. Phase 1/2 NCT03252847 and phase 3 LUMEOS NCT04671433. Formerly MGT009 / AAV-RPGR. The J&J product page first cited for the AAV5/RPGR facts has gone; they now rest on the Retinal Physician and Ophthalmology Management reviews, which say the same.

How to cite

botaretigene sparoparvovec (AXP000260.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000260.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.